A prodrug form of VRT-043198
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

VX-765

Item No. 28825

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-(4-amino-3-chlorobenzoyl)-3-methyl-L-valyl-N-[(2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl]-L-prolinamide
CAS Number
273404-37-8
Synonyms
  • Belnacasan
Molecular Formula
C24H33ClN4O6
Formula Weight
509.0
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlEthanol: 30 mg/mlEthanol:PBS (pH 7.2) (1:9): 0.1 mg/ml
λmax
281 nm
SMILES
NC1=C(Cl)C=C(C(N[C@@H](C(C)(C)C)C(N2CCC[C@H]2C(N[C@@H]3[C@H](OCC)OC(C3)=O)=O)=O)=O)C=C1
InChi Code
InChI=1S/C24H33ClN4O6/c1-5-34-23-16(12-18(30)35-23)27-21(32)17-7-6-10-29(17)22(33)19(24(2,3)4)28-20(31)13-8-9-15(26)14(25)11-13/h8-9,11,16-17,19,23H,5-7,10,12,26H2,1-4H3,(H,27,32)(H,28,31)/t16-,17-,19+,23+/m0/s1
InChi Key
SJDDOCKBXFJEJB-MOKWFATOSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $69

    Add

    10 mg

    $115

    Add

    25 mg

    $263

    Add

    50 mg

    $493

    Add
    Product Description

    VX-765 is a prodrug form of the caspase-1 inhibitor VRT-043198.1 VX-765 (50, 100, and 200 mg/kg) inhibits LPS-induced increases in serum IL-1β levels in mice. It also reduces oxazolone-induced ear edema and levels of IL-1β, IL-18, and IFN-γ in ear tissue in an oxazolone-sensitized mouse model of delayed-type hypersensitivity. VX-765 reduces forepaw inflammation in a mouse model of collagen-induced arthritis in a dose-dependent manner. VX-765 (≥50 mg/kg) decreases seizure duration and the number of seizures in a mouse model of acute seizures induced by hippocampal kainic acid injection, as well as delays the onset of seizures when administered at doses of 100 and 200 mg/kg.2 It also reduces the aggregated duration of epileptic activity in a mouse model of chronic epilepsy.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Wannamaker, W., Davies, R., Namchuk, M., et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1β and IL-18. J. Pharmacol. Exp. Ther. 321(2), 509-516 (2007).

    2. Maroso, M., Balosso, S., Rivizza, T., et al. Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics 8(2), 304-315 (2011).